Table 3 Data available for analysis of all treatment comparisons used in intervention studies by population and study characteristics
| Â | Â | n | Genotype 1 n (%) | Genotype 2 n (%) | Genotype 3 n (%) |
|---|---|---|---|---|---|
Prior treatment status | Treatment Experienced | 47 | 15 (30.61) | 9 (34.62) | 23 (45.1) |
Treatment Naïve | 79 | 34 (69.39) | 17 (65.38) | 28 (54.9) | |
Population | All Patients | 61 | 27 (55.1) | 13 (50) | 21 (41.18) |
With Cirrhosis | 39 | 14 (28.57) | 8 (30.77) | 17 (33.33) | |
Without Cirrhosis | 26 | 8 (16.33) | 5 (19.23) | 13 (25.49) | |
Articles | Linas, 2015 | 20 | 0 (0) | 6 (23.08) | 14 (27.45) |
Liu, 2014 | 1 | 1 (2.04) | 0 (0) | 0 (0) | |
Najafzadeh, 2015 | 3 | 1 (2.04) | 1 (3.85) | 1 (1.96) | |
Saab, 2014 | 16 | 16 (32.65) | 0 (0) | 0 (0) | |
SanMiguel, 2014 | 8 | 2 (4.08) | 2 (7.69) | 4 (7.84) | |
Cure, 2015 (Italy) | 31 | 14 (28.57) | 8 (30.77) | 9 (17.65) | |
Cure, 2015 (UK) | 13 | 4 (8.16) | 4 (15.38) | 5 (9.8) | |
Pfeil, 2015 | 34 | 11 (22.45) | 5 (19.23) | 18 (35.29) | |
Treatments | SOF PEG RBV 12 wk. vs BOC PEG RBV 48 wk | 14 | 14 (28.57) | 0 (0) | 0 (0) |
SOF PEG RBV 12 wk. vs No Tx | 7 | 4 (8.16) | 0 (0) | 3 (5.88) | |
SOF PEG RBV 12 wk. vs PEG RBV 24 wk | 11 | 0 (0) | 2 (7.69) | 9 (17.65) | |
SOF PEG RBV 12 wk. vs PEG RBV 48 wk | 19 | 13 (26.53) | 0 (0) | 6 (11.76) | |
SOF PEG RBV 12 wk. vs TEL PEG RBV 48 wk | 11 | 11 (22.45) | 0 (0) | 0 (0) | |
SOF RBV 12 wk. vs No Tx | 16 | 0 (0) | 12 (46.15) | 4 (7.84) | |
SOF RBV 12 wk. vs PEG RBV 24 wk | 10 | 0 (0) | 8 (30.77) | 2 (3.92) | |
SOF RBV 12 wk. vs PEG RBV 48 wk | 4 | 0 (0) | 4 (15.38) | 0 (0) | |
SOF RBV 24 wk. vs No Tx | 22 | 6 (12.24) | 0 (0) | 16 (31.37) | |
SOF RBV 24 wk. vs PEG RBV 24 wk | 7 | 0 (0) | 0 (0) | 7 (13.73) | |
SOF RBV 24 wk. vs PEG RBV 48 wk | 5 | 1 (2.04) | 0 (0) | 4 (7.84) | |
Total | Â | 126 | 49 (38.89) | 26 (20.63) | 51 (40.48) |